Lower-Dose Rituximab Demonstrates Long-Term Efficacy in Neuromyelitis Optica Spectrum Disorder

For the majority of patients who were either aquaporin-4-antibody seropositive or seronegative, rituximab was the first disease-modifying therapy administered for neuromyelitis optica spectrum disorder.:

Source: Neurology Read More